The pathologic complete response rate was 66.3% in the nab-paclitaxel arm and 57.6% in the docetaxel-carboplatin arm. The combination of nab-paclitaxel, trastuzumab, and pertuzumab may provide ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

There is now a wealth of evidence that demonstrates weight bias is reported by people of all ages and backgrounds, and discrimination has been evidenced across a range of settings including workplaces ...

that could see the drug being used in advanced breast cancer with even lower levels of the HER2 biomarker. The marketing application for Enhertu (trastuzumab deruxtecan) is based on the results of ...

Research is underway on the immune-stimulating antibody conjugate BDC-1001’s effectiveness against HER2-positive cancers when combined with Perjeta, according to data presented at SABCS. The Food and ...